Utipro® Plus AF available for launch We are pleased to announce the availability for launch of a new formulation of UTIPRO® PLUS, our product for uncomplicated UTIs. This version of the product, totally free from animal derivatives, is commercialized under the brand Utipro® Plus AF, whereas AF stands for Advanced Formulation. In [...]
We are pleased to announce the launch of UTIPRO® PLUS, our product for uncomplicated UTIs, in Finland. The product is commercialized over the Finnish territory under the umbrella brand UrinCUR / Utipro plus and it is distributed by RFSU, our partner for the product on the Swedish and Norwegian territory [...]
News on NOVENTURE participation at EAU 2019 in BARCELONA For the fourth consecutive year, Noventure was present at the annual congress of the EAU – European Association of Urology- that took place in Barcelona 15th – 19th March 2019. Noventure participation to EAU is to confirm its presence in the [...]
TASECTAN® launched in Croatia by JGL. Noventure is proud to announce the launch of TASECTAN® in Croatia by its partner company JGL, under the brand Normia Stop. TASECTAN® acts by forming a film which protects the intestinal mucosa, reducing the frequency and duration of diarrhea episodes in adults, children and [...]
Noventure is proud to announce the launch of XILAPLUS® in France by its long-term partner company Therabel, under the brand name Diastil Diarrhée. XILAPLUS® is specifically formulated for the control and reduction of diarrheal events of various etiologies. It acts by forming a film which protects the intestinal mucosa, reducing the [...]
Following the launch of Rinonet-Rhinosectan® in the Spanish market last April, for the first year Noventure has participated in the annual congress of the EAACI – European Academy of Allergy and Clinical Immunology that took place in Munich 27th – 29th May 2018. Noventure participated in this congress to announce [...]
As in previous years, Noventure has participated in the ESPGHAN Congress, held in Geneva, 09-12 May 2018. Pediatric gastroenterologists are a key target group for the recommendation and endorsement of new approaches to GI conditions in children. 4.627 delegates from 100 countries participated at the congress, and many of them [...]
For the third consecutive year, Noventure has participated in the annual congress of the EAU – European Association of Urology that took place in Copenhagen 17th – 19th March 2018 with about 11,000 participants, coming from 123 countries all over the world. During the Congress 273 scientific sessions included 2,656 presentations [...]
Thorpe KE, Joski P, Johnston KJ. Health Aff (Millwood) 2018 Apr;37(4):662-669. doi: 10.1377/hlthaff.2017.1153. Epub 2018 Mar 21. Abstract Antibiotic-resistant infections are a global health care concern. The Centers for Disease Control and Prevention estimates that 23,000 Americans with these infections die each year. Rising infection rates add to the costs of [...]
Adiarin® is recommended for the protection of gut lining in diarrhea in children and adults. It is the first Noventure product in Russia. Tasectan® in Europe is a class III medical device and complies with the Essential Requirements of Directive 93/42/EEC and subsequent amendments. (CE 0373, Novinthetical Pharma SA). In [...]